Compare MCD & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCD | NVO |
|---|---|---|
| Founded | 1940 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 226.8B | 269.6B |
| IPO Year | N/A | N/A |
| Metric | MCD | NVO |
|---|---|---|
| Price | $325.78 | $49.33 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 24 | 10 |
| Target Price | ★ $333.09 | $54.25 |
| AVG Volume (30 Days) | 3.1M | ★ 27.8M |
| Earning Date | 02-11-2026 | 02-04-2026 |
| Dividend Yield | 2.27% | ★ 2.58% |
| EPS Growth | ★ 2.90 | 1.77 |
| EPS | ★ 11.72 | 3.62 |
| Revenue | $26,264,000,000.00 | ★ $48,588,245,669.00 |
| Revenue This Year | $3.98 | $1.02 |
| Revenue Next Year | $5.84 | $6.81 |
| P/E Ratio | $27.92 | ★ $12.90 |
| Revenue Growth | 1.25 | ★ 6.43 |
| 52 Week Low | $283.47 | $43.08 |
| 52 Week High | $328.06 | $93.80 |
| Indicator | MCD | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 67.81 | 40.62 |
| Support Level | $321.24 | $43.24 |
| Resistance Level | $328.06 | $64.16 |
| Average True Range (ATR) | 4.72 | 2.26 |
| MACD | 1.66 | -1.91 |
| Stochastic Oscillator | 87.78 | 29.78 |
McDonald's is the world's largest restaurant brand, with nearly $131 billion in systemwide sales across more than 44,000 restaurants and over 100 markets. The quick-service chain built its early reputation on speed, consistency, and affordable hamburgers, and today its global menu spans burgers, chicken, breakfast, and beverages that have helped popularize American fast-food cuisine worldwide. The firm derives the bulk of its revenue from franchise royalties and rent (about 61%), with the remainder stemming from company-operated restaurants across three segments: the United States (41% of systemwide sales), international operated markets (34%), and international developmental/licensed markets (25%).
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.